A&L Canada Laboratories Inc. (“A&L”), a leader in analytical services and technologies, and TruTrace Technologies Inc. (CSE:TTT; OTC:TTTSF) (“TruTrace” or the “Company”), creator of the first fully-integrated blockchain platform that registers and tracks intellectual property for the cannabis industry, today announced that A&L will be one of the inaugural testing facilities in the Shoppers Drug Mart (“Shoppers”) and TruTrace Technologies medical cannabis verification pilot program (the “Pilot Program”).

As announced by Shoppers at the second annual World Cannabis Congress, the Pilot Program is built on TruTrace’s proprietary StrainSecure™ platform, which focuses on testing and verification to confirm the origin, authenticity and quality assurance of cannabis products.


A&L was one of the earliest testing facilities to receive a Health Canada testing license under the Access to Cannabis for Medical Purposes Regulations (ACMPR) and provides a wide range of analytical services to the cannabis industry. A&L was recently presented the award for the Best Testing Facility at the 2019 O’Cannabiz Awards Gala – a national annual event honouring cannabis professionals and companies, recognizing excellence and innovation in the industry.

“We provide the full range of services required by TruTrace and Shoppers, and we are proud to support the transparency and accountability goals of this Pilot Program. Our capabilities in testing through all stages of the cannabis production cycle will fully support the quality assurance mandate of Shoppers,” said Nevin McDougall, President and Chief Commercial Officer of A&L.

“We are very pleased to have secured the support of A&L to provide an essential element of the Pilot Program,” said TruTrace Technologies CEO Robert Galarza. “A fundamental objective of the program is to provide complete assurance to medical patients about the origins and quality of their cannabis. A&L’s testing services are a key aspect of meeting that objective.”

A&L will support the project by working with other pilot partners such as WeedMD Inc. and Zenabis Global to provide final test data on medical cannabis products, validating the functionality of the TruTrace platform and meeting the quality assurance requirements of Shoppers and the Canadian consumer.

The full diagnostic capabilities of A&L Canada Laboratories for the cannabis industry can be found on the company web-site at https://www.alcanada.com/cannabistesting.

About A&L Canada Laboratories

We are an innovative, research driven technology company focused on sustainable development. Through leading expertise, modern laboratory facilities and strong customer focus, A&L serves a wide range of industries including Agriculture, Environmental, Food & Pharma – globally.

In Agriculture, A&L provides comprehensive analytical services for soil, plant tissue, feed, fertilizer, and water. A&L’s services also include production recommendations, remote sensing and precision agriculture capabilities. A&L Biologicals Inc. focuses on research and development of biological compounds for use in agricultural production systems.  The A&L Environmental division provides organic and inorganic chemistry and general chemistry using state of the art technology and methodology.  For Food & Pharma, A&L provides analytical services for plant tissue, water, media and finished product. A&L’s services for cannabis and hemp also include disease diagnostics, genetic analysis, production recommendations, Plant Monitoring Program and Health Canada required testing.  The company operates two world class analytical Laboratories serving clients throughout Canada, the U.S. and Internationally.

Visit our website at www.alcanada.com. Follow us on twitter @alcannabislabs.

About TruTrace Technologies:

TruTrace Technologies has developed the first integrated blockchain platform to register and track intellectual property in the cannabis industry. TruTrace’s technology allows cannabis growers and breeders to identify and secure rights to their intellectual property. It also streamlines the administrative process and reduces the costs of genetic and mandatory quality-control testing for legal cannabis. TruTrace’s technology is proprietary, immutable and cryptographically secure, thereby establishing an accurate and permanent account for cannabis strains from ownership to market.

Disclaimer for Forward-Looking Information

This news release includes forward-looking information within the meaning of Canadian securities legislation, concerning the business of TruTrace, including statements regarding: A&L’s participation in the Pilot Program; that use of the platform is intended to enable A&L to provide final test data on medical cannabis products validating the functionality of the TruTrace platform and meeting the quality assurance requirements of Shoppers and the Canadian consumer; and the ability of TruTrace Technologies’ platform to bring transparency and integrity to the cannabis industry. Although the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because the Company can give no assurance that it will prove to be correct and actual results and future events could differ materially from those anticipated in such information. Forward-looking information necessarily involves known and unknown risks, including, without limitation, risks associated with: general economic conditions; that A&L’s participation in the Pilot Program may not result in the expected results of the Pilot Program or support the quality assurance mandate of Shoppers; whether sufficient numbers of researchers, clinicians, physicians, pharmacists and patients will be available to participate in the Pilot Program; potential negative results of the Pilot Program; adverse industry events; loss of markets; future legislative and regulatory developments in Canada, the United States, and elsewhere; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favourable terms; and other risks beyond the Company’s control. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties and other factors, many of which are beyond the control of the Company. Readers are cautioned not to place undue reliance on any forward-looking information contained in this news release. Forward-looking information contained in this news release is provided as of the date of this news release. The Company disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

SOURCE TruTrace Technologies Inc.

For further information: A&L Canada Laboratories: Nevin McDougall, President & Chief Commercial Officer, nmcdougall@alcanada.com; Greg Patterson, CEO and Founder, patterson@alcanada.com, 1-519-457-2575, www.alcanada.com; TruTrace Technologies Inc: Robert Galarza, Chief Executive Officer and Director; Media Relations: Corey Herscu, RNMKR Agency, 416-300-3030, corey@rnmkr.agency; Investor Inquiries: Swapan Kakumanu, Chief Financial Officer, 403-681-2549, swapan@trutrace.co

Click here to connect with TruTrace Technologies Inc. (TSXV:TTT, OTC:BKKSF) for an Investor Presentation.

Source: www.newswire.ca

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less